Drug treatment of type 2 diabetes: Its cost is significantly associated with HbA1c levels

Drug treatment of type 2 diabetes: Its cost is significantly associated with HbA1c levels

Aims To examine the relationship between costs of hyperglycaemia drug treatment and glycemic control amongst people with type 2 diabetes (T2D). Methods This observational study utilised data from the QUALIDIAB database on 3,452 T2D patients seen in Diabetes Centers in Argentina. Patients were classi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of clinical practice (Esher) 2019-04, Vol.73 (4), p.e13336-n/a
Hauptverfasser: Elgart, Jorge F., Silvestrini, Constanza, Prestes, Mariana, Gonzalez, Lorena, Rucci, Enzo, Gagliardino, Juan J.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 4
container_start_page e13336
container_title International journal of clinical practice (Esher)
container_volume 73
creator Elgart, Jorge F.
Silvestrini, Constanza
Prestes, Mariana
Gonzalez, Lorena
Rucci, Enzo
Gagliardino, Juan J.
description Aims To examine the relationship between costs of hyperglycaemia drug treatment and glycemic control amongst people with type 2 diabetes (T2D). Methods This observational study utilised data from the QUALIDIAB database on 3,452 T2D patients seen in Diabetes Centers in Argentina. Patients were classified according to their HbA1c value into two groups: on target (OT; HbA1c ≤ 7%), and not on target (NOT; HbA1c > 7%); within each category we considered clinical and metabolic indicators, as well as type of hyperglycaemia treatment. Monthly expenditure on drugs was estimated by micro‐costing. Multivariable regression analysis was used to evaluate the association between cost of hyperglycaemia treatment and HbA1c values. Results In total, 48.9% of the participants have HbA1c OT values. Overall monthly per capita costs of this treatment increased significantly (134%) in the NOT group. Multivariable regression analysis showed that expenditure for hyperglycaemia drugs treatment was significant associated with glycemic control (OR: 0.705), diabetes duration (OR: 1.017), systolic blood pressure (OR: 1.006) and treatment of T2D (OR: 2.622). Conclusions HbA1c NOT significantly increases drugs monthly cost of hyperglycaemia treatment in people with T2D in a country with an emerging market economy.
doi_str_mv 10.1111/ijcp.13336
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2187027351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2187027351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3656-4c9c58fb7acb9923c59adeaca4d71ef3e40804254d33eb2c17330bef6b37fd713</originalsourceid><addsrcrecordid>eNp9kDtPwzAURi0EoqWw8AOQR4SU4kcSJ2xVebSoEgwwMFmOc11c5VFihyr_npQAI3f57nB0hoPQOSVT2t-13ejtlHLO4wM0piJkAWUhPex_HidBRDgdoRPnNoSwKErIMRpxklAqBBmjt9umXWPfgPIlVB7XBvtuC5jh3KoMPLgbvPQO69p5bB12dl1ZY7WqfNFh5VytrfKQ453173iRzajGBXxC4U7RkVGFg7OfnaDX-7uX-SJYPT0s57NVoHkcxUGoUx0lJhNKZ2nKuI5SlYPSKswFBcMhJAkJWRTmnEPGNBWckwxMnHFheoRP0OXg3Tb1RwvOy9I6DUWhKqhbJxlNBGGCR3v0akB1UzvXgJHbxpaq6SQlcp9S7lPK75Q9fPHjbbMS8j_0t10P0AHY2QK6f1Ry-Th_HqRfGNB-Zw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2187027351</pqid></control><display><type>article</type><title>Drug treatment of type 2 diabetes: Its cost is significantly associated with HbA1c levels</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Elgart, Jorge F. ; Silvestrini, Constanza ; Prestes, Mariana ; Gonzalez, Lorena ; Rucci, Enzo ; Gagliardino, Juan J.</creator><creatorcontrib>Elgart, Jorge F. ; Silvestrini, Constanza ; Prestes, Mariana ; Gonzalez, Lorena ; Rucci, Enzo ; Gagliardino, Juan J.</creatorcontrib><description>Aims To examine the relationship between costs of hyperglycaemia drug treatment and glycemic control amongst people with type 2 diabetes (T2D). Methods This observational study utilised data from the QUALIDIAB database on 3,452 T2D patients seen in Diabetes Centers in Argentina. Patients were classified according to their HbA1c value into two groups: on target (OT; HbA1c ≤ 7%), and not on target (NOT; HbA1c &gt; 7%); within each category we considered clinical and metabolic indicators, as well as type of hyperglycaemia treatment. Monthly expenditure on drugs was estimated by micro‐costing. Multivariable regression analysis was used to evaluate the association between cost of hyperglycaemia treatment and HbA1c values. Results In total, 48.9% of the participants have HbA1c OT values. Overall monthly per capita costs of this treatment increased significantly (134%) in the NOT group. Multivariable regression analysis showed that expenditure for hyperglycaemia drugs treatment was significant associated with glycemic control (OR: 0.705), diabetes duration (OR: 1.017), systolic blood pressure (OR: 1.006) and treatment of T2D (OR: 2.622). Conclusions HbA1c NOT significantly increases drugs monthly cost of hyperglycaemia treatment in people with T2D in a country with an emerging market economy.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/ijcp.13336</identifier><identifier>PMID: 30811770</identifier><language>eng</language><publisher>England</publisher><ispartof>International journal of clinical practice (Esher), 2019-04, Vol.73 (4), p.e13336-n/a</ispartof><rights>2019 John Wiley &amp; Sons Ltd</rights><rights>This article is protected by copyright. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3656-4c9c58fb7acb9923c59adeaca4d71ef3e40804254d33eb2c17330bef6b37fd713</citedby><cites>FETCH-LOGICAL-c3656-4c9c58fb7acb9923c59adeaca4d71ef3e40804254d33eb2c17330bef6b37fd713</cites><orcidid>0000-0002-6101-1219</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijcp.13336$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijcp.13336$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30811770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Elgart, Jorge F.</creatorcontrib><creatorcontrib>Silvestrini, Constanza</creatorcontrib><creatorcontrib>Prestes, Mariana</creatorcontrib><creatorcontrib>Gonzalez, Lorena</creatorcontrib><creatorcontrib>Rucci, Enzo</creatorcontrib><creatorcontrib>Gagliardino, Juan J.</creatorcontrib><title>Drug treatment of type 2 diabetes: Its cost is significantly associated with HbA1c levels</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Aims To examine the relationship between costs of hyperglycaemia drug treatment and glycemic control amongst people with type 2 diabetes (T2D). Methods This observational study utilised data from the QUALIDIAB database on 3,452 T2D patients seen in Diabetes Centers in Argentina. Patients were classified according to their HbA1c value into two groups: on target (OT; HbA1c ≤ 7%), and not on target (NOT; HbA1c &gt; 7%); within each category we considered clinical and metabolic indicators, as well as type of hyperglycaemia treatment. Monthly expenditure on drugs was estimated by micro‐costing. Multivariable regression analysis was used to evaluate the association between cost of hyperglycaemia treatment and HbA1c values. Results In total, 48.9% of the participants have HbA1c OT values. Overall monthly per capita costs of this treatment increased significantly (134%) in the NOT group. Multivariable regression analysis showed that expenditure for hyperglycaemia drugs treatment was significant associated with glycemic control (OR: 0.705), diabetes duration (OR: 1.017), systolic blood pressure (OR: 1.006) and treatment of T2D (OR: 2.622). Conclusions HbA1c NOT significantly increases drugs monthly cost of hyperglycaemia treatment in people with T2D in a country with an emerging market economy.</description><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kDtPwzAURi0EoqWw8AOQR4SU4kcSJ2xVebSoEgwwMFmOc11c5VFihyr_npQAI3f57nB0hoPQOSVT2t-13ejtlHLO4wM0piJkAWUhPex_HidBRDgdoRPnNoSwKErIMRpxklAqBBmjt9umXWPfgPIlVB7XBvtuC5jh3KoMPLgbvPQO69p5bB12dl1ZY7WqfNFh5VytrfKQ453173iRzajGBXxC4U7RkVGFg7OfnaDX-7uX-SJYPT0s57NVoHkcxUGoUx0lJhNKZ2nKuI5SlYPSKswFBcMhJAkJWRTmnEPGNBWckwxMnHFheoRP0OXg3Tb1RwvOy9I6DUWhKqhbJxlNBGGCR3v0akB1UzvXgJHbxpaq6SQlcp9S7lPK75Q9fPHjbbMS8j_0t10P0AHY2QK6f1Ry-Th_HqRfGNB-Zw</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Elgart, Jorge F.</creator><creator>Silvestrini, Constanza</creator><creator>Prestes, Mariana</creator><creator>Gonzalez, Lorena</creator><creator>Rucci, Enzo</creator><creator>Gagliardino, Juan J.</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6101-1219</orcidid></search><sort><creationdate>201904</creationdate><title>Drug treatment of type 2 diabetes: Its cost is significantly associated with HbA1c levels</title><author>Elgart, Jorge F. ; Silvestrini, Constanza ; Prestes, Mariana ; Gonzalez, Lorena ; Rucci, Enzo ; Gagliardino, Juan J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3656-4c9c58fb7acb9923c59adeaca4d71ef3e40804254d33eb2c17330bef6b37fd713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elgart, Jorge F.</creatorcontrib><creatorcontrib>Silvestrini, Constanza</creatorcontrib><creatorcontrib>Prestes, Mariana</creatorcontrib><creatorcontrib>Gonzalez, Lorena</creatorcontrib><creatorcontrib>Rucci, Enzo</creatorcontrib><creatorcontrib>Gagliardino, Juan J.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elgart, Jorge F.</au><au>Silvestrini, Constanza</au><au>Prestes, Mariana</au><au>Gonzalez, Lorena</au><au>Rucci, Enzo</au><au>Gagliardino, Juan J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug treatment of type 2 diabetes: Its cost is significantly associated with HbA1c levels</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2019-04</date><risdate>2019</risdate><volume>73</volume><issue>4</issue><spage>e13336</spage><epage>n/a</epage><pages>e13336-n/a</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Aims To examine the relationship between costs of hyperglycaemia drug treatment and glycemic control amongst people with type 2 diabetes (T2D). Methods This observational study utilised data from the QUALIDIAB database on 3,452 T2D patients seen in Diabetes Centers in Argentina. Patients were classified according to their HbA1c value into two groups: on target (OT; HbA1c ≤ 7%), and not on target (NOT; HbA1c &gt; 7%); within each category we considered clinical and metabolic indicators, as well as type of hyperglycaemia treatment. Monthly expenditure on drugs was estimated by micro‐costing. Multivariable regression analysis was used to evaluate the association between cost of hyperglycaemia treatment and HbA1c values. Results In total, 48.9% of the participants have HbA1c OT values. Overall monthly per capita costs of this treatment increased significantly (134%) in the NOT group. Multivariable regression analysis showed that expenditure for hyperglycaemia drugs treatment was significant associated with glycemic control (OR: 0.705), diabetes duration (OR: 1.017), systolic blood pressure (OR: 1.006) and treatment of T2D (OR: 2.622). Conclusions HbA1c NOT significantly increases drugs monthly cost of hyperglycaemia treatment in people with T2D in a country with an emerging market economy.</abstract><cop>England</cop><pmid>30811770</pmid><doi>10.1111/ijcp.13336</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-6101-1219</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1368-5031
ispartof International journal of clinical practice (Esher), 2019-04, Vol.73 (4), p.e13336-n/a
issn 1368-5031
1742-1241
language eng
recordid cdi_proquest_miscellaneous_2187027351
source Wiley Online Library Journals Frontfile Complete
title Drug treatment of type 2 diabetes: Its cost is significantly associated with HbA1c levels
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T01%3A32%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20treatment%20of%20type%202%20diabetes:%20Its%20cost%20is%20significantly%20associated%20with%20HbA1c%20levels&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Elgart,%20Jorge%20F.&rft.date=2019-04&rft.volume=73&rft.issue=4&rft.spage=e13336&rft.epage=n/a&rft.pages=e13336-n/a&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/ijcp.13336&rft_dat=%3Cproquest_cross%3E2187027351%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2187027351&rft_id=info:pmid/30811770&rfr_iscdi=true